Posted 28 March, 2024
Boundless Bio, Inc. IPO completed
IPO completed detected for ticker Nasdaq:BOLD in a 424B4 filed on 28 March, 2024.
This is the initial public offering of shares of common stock by Boundless Bio, Inc.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Boundless Bio, Inc.
Health Care/Life Sciences • Biotechnology
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.Market Cap
$37.9M
View Company Details
$37.9M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.